Volume 3, Issue 11 (Autumn 2017)                   Caspian.J.Neurol.Sci 2017, 3(11): 214-221 | Back to browse issues page

XML Print

1- Iranian Multiple Sclerosis and Neuroimmunology Research Center, Isfahan, Iran
2- School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
3- Iranian Multiple Sclerosis and Neuroimmunology Research Center, Isfahan, Iran; keyvanghadimi@yahoo.com
4- Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
Abstract:   (315 Views)
Background: Multiple sclerosis (MS) is one of the most common autoimmune diseases in adults that cause disability in patients. Different studies were conducted on more rapid diagnosis of the disease such as measuring serum or cerebrospinal fluid (CSF) contents.
Objectives: The current study aimed at measuring amyloid β (Aβ) serum levels in patients with relapsing-remitting MS.
Materials and Methods: In the current case-control study, the serum levels of Aβ were measured in 48 patients with RRMS and 33 healthy controls using the enzyme-linked immunosorbent assay (ELISA) technique in Isfahan, Iran, from 2014 to 2016. Data analysis was conducted with SPSS.
Results: The mean serum level of Aβ in the case (patients with RRMS) and control groups were 192.75±125.65 and 128.11±85.20 pg/mL, respectively; so serum Aβ levels in the RRMS group was significantly higher than healthy controls (p=0.02). Also, there was a positive significant correlation between the serum Aβ levels and the expanded disability status scale (EDSS) (r=+0.85, p<0.0001).
Conclusions: Owing to the increase of serum Aβ level in patients with RRMS and its significant increase in severe MS cases (higher EDSS scores), so serum Aβ level can be considered as a marker for MS and its progression.
Full-Text [PDF 538 kb]   (85 Downloads) |   |   Full-Text (HTML)  (8 Views)  
Type of Study: Research | Subject: Special
Received: 2017/11/30 | Accepted: 2017/11/30 | Published: 2017/11/30

1. Steinman L. Immunology of Relapse and Remission in Multiple Sclerosis. Annu Rev Immunol 2014; 32:257-81 [DOI:10.1146/annurev-immunol-032713-120227] [PMID]
2. Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, et al. The Relation between Inflammation and Neurodegeneration in Multiple Sclerosis Brains. Brain 2009;132(5):1175-89. [DOI:10.1093/brain/awp070] [PMID] [PMCID]
3. Bjartmar C, Kidd G, Mörk S, Rudick R, Trapp BD. Neurological Disability Correlates with Spinal Cord Axonal Loss and Reduced N‐acetyl Aspartate in Chronic Multiple Sclerosis Patients. Ann Neurol 2000;48(6):893-901. https://doi.org/10.1002/1531-8249(200012)48:6<893::AID-ANA10>3.0.CO;2-B [DOI:10.1002/1531-8249(200012)48:63.0.CO;2-B]
4. Kuhlmann T, Miron V, Cuo Q, Wegner C, Antel J, Brück W. Differentiation Block of Oligodendroglial Progenitor Cells as a Cause for Remyelination Failure in Chronic Multiple Sclerosis. Brain 2008;131(7):1749-58. [DOI:10.1093/brain/awn096] [PMID]
5. Lucchinetti CF, Brueck W, Rodriguez M, Lassmann H. Multiple Sclerosis: Lessons from Neuropathology. Semin Neurol 1998;18(3):337-49. [DOI:10.1055/s-2008-1040885] [PMID]
6. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal Fluid and Plasma Biomarkers in Alzheimer Disease. Nat Rev Neurosci 2010;6(3):131-44. [DOI:10.1038/nrneurol.2010.4]
7. Gisslén M, Krut J, Andreasson U, Blennow K, Cinque P, Brew BJ, et al. Amyloid and tau Cerebrospinal Fluid Biomarkers in HIV Infection. BMC Neurol 2009;9(1):63. [DOI:10.1186/1471-2377-9-63] [PMID] [PMCID]
8. Sjögren M, Gisslén M, Vanmechelen E, Blennow K. Low Cerebrospinal Fluid β-amyloid 42 in Patients with Acute Bacterial Meningitis and Normalization after Treatment. Neurosci Lett 2001;314(1):33-6. [DOI:10.1016/S0304-3940(01)02285-6]
9. Trysberg E, Höglund K, Svenungsson E, Blennow K, Tarkowski A. Decreased Levels of Soluble Amyloid β-protein Precursor and β-amyloid Protein in Cerebrospinal Fluid of Patients with Systemic Lupus Erythematosus. Arthritis Res Ther 2004;6(2):R129- R36. [DOI:10.1186/ar1040] [PMID] [PMCID]
10. Mattsson N, Axelsson M, Haghighi S, Malmeström C, Wu G, Anckarsäter R, et al. Reduced Cerebrospinal Fluid BACE1 Activity in Multiple Sclerosis. Mult Scler J 2009;15(4):448-54. [DOI:10.1177/1352458508100031] [PMID]
11. Mattsson N, Bremell D, Anckarsäter R, Blennow K, Anckarsäter H, Zetterberg H, et al. Neuroinflammation in Lyme Neuroborreliosis Affects Amyloid Metabolism. BMC Neurol 2010;10(1):51. [DOI:10.1186/1471-2377-10-51] [PMID] [PMCID]
12. Gehrmann J, Banati RB, Cuzner ML, Kreutzberg GW, Newcombe J. Amyloid Precursor Protein (APP) Expression in Multiple Sclerosis Lesions. Glia 1995;15(2):141-51. [DOI:10.1002/glia.440150206] [PMID]
13. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal Transection in the Lesions of Multiple Sclerosis. N Engl J Med 1998;338(5):278-85. [DOI:10.1056/NEJM199801293380502] [PMID]
14. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal Damage in Acute Multiple Sclerosis Lesions. Brain 1997;120(3):393-9. [DOI:10.1093/brain/120.3.393] [PMID]
15. Grant JL, Ghosn EEB, Axtell RC, Herges K, Kuipers HF, Woodling NS, et al. Reversal of Paralysis and Reduced Inflammation from Peripheral Administration of β-amyloid in TH1 and TH17 Versions of Experimental Autoimmune Encephalomyelitis. Sci Transl Med 2012;4(145):145ra05.
16. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria. Ann Neurol 2011;69(2):292-302. [DOI:10.1002/ana.22366] [PMID] [PMCID]
17. Ziemssen T. Multiple Sclerosis Beyond EDSS: Depression and Fatigue. J Neurol Sci 2009; 277 Suppl 1:S37-41. [DOI:10.1016/S0022-510X(09)70011-5]
18. Augutis K, Axelsson M, Portelius E, Brinkmalm G, Andreasson U, Gustavsson MK, et al. Cerebrospinal Fluid Biomarkers of β-amyloid Metabolism in Multiple Sclerosis. Mult Scler J 2013;19(5):543-52. [DOI:10.1177/1352458512460603] [PMID]
19. Pietroboni AM, Schiano di Cola F, Scarioni M, Fenoglio C, Spanò B, Arighi A, et al. CSF β-amyloid as a Putative Biomarker of Disease Progression in Multiple Sclerosis. Mult Scler 2016;23(8):1085-91. [DOI:10.1177/1352458516674566] [PMID]
20. Mai W, Hu X, Lu Z, Peng F, Wang Y. Cerebrospinal Fluid Levels of Soluble Amyloid Precursor Protein and β-amyloid 42 in Patients with Multiple Sclerosis, Neuromyelitis Optica and Clinically Isolated Syndrome. J Int Med Res 2011;39(6):2402-13. [DOI:10.1177/147323001103900641] [PMID]
21. Mori F, Rossi S, Sancesario G, Codecà C, Mataluni G, Monteleone F, et al. Cognitive and Cortical Plasticity Deficits Correlate with Altered Amyloid-β CSF Levels in Multiple Sclerosis. Neuropsychopharmacology 2011;36(3):559-68. [DOI:10.1038/npp.2010.187] [PMID] [PMCID]
22. Clarner T, Buschmann JP, Beyer C, Kipp M. Glial Amyloid Precursor Protein Expression Is Restricted to Astrocytes in an Experimental Toxic Model of Multiple Sclerosis. J Mol Neurosci 2011;43(3):268-74. [DOI:10.1007/s12031-010-9419-9] [PMID]
23. Yokote H, Yagi Y, Watanabe Y, Amino T, Kamata T, Mizusawa H. Serum Amyloid A Level Is Increased in Neuromyelitisoptica and Atypical Multiple Sclerosis with Smaller T2 Lesion Volume in Brain MRI. J Neuroimmunol 2013;259(1):92-5. [DOI:10.1016/j.jneuroim.2013.03.004] [PMID]
24. Ristori G, Laurenti F, Stacchini P, Gasperini C, Buttinelli C, Pozzilli C, et al. Serum Amyloid A Protein Is Elevated in Relapsing–remitting Multiple Sclerosis. J Neuroimmunol 1998;88(1):9-12. [DOI:10.1016/S0165-5728(98)00037-X]
25. Schroder R, Nennesmo I, Linke RP. Amyloid in a Multiple Sclerosis Lesion Is Clearly of A Lambda Type. Acta Neuropathol 2000;100(6):709-11. [DOI:10.1007/s004010000244] [PMID]